Azitra (AZTR) Capital Expenditures (2022 - 2026)

Azitra's (AZTR) quarterly Capital Expenditures came in at $14928.0 in Q1 2026, up 61.4% on a QoQ basis from $9249.0 in Q4 2025.

Azitra (AZTR) Capital Expenditures (2022 - 2026) Analysis & Trends

Azitra (AZTR) has 5 years of Capital Expenditures data on file, last reported at $14928.0 in Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to $14928.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39141.0 (up 356.77% YoY) and the FY2025 annual result came in at $24213.0, up 182.57% from the prior year.
Capital Expenditures improved to $14928.0 in Q1 2026, from $9249.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $15192.0 in Q4 2022 to a low of -$4265.0 in Q2 2023.
A 5-year average of $9490.8 and a median of $11601.0 in 2025 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2023 — Capital Expenditures slumped 76.95% — and 2024, when it surged 148.67%.
Tracing AZTR's Capital Expenditures over 5 years: stood at $15192.0 in 2022, then retreated by 14.62% to $12971.0 in 2023, then slumped by 33.94% to $8569.0 in 2024, then climbed by 7.94% to $9249.0 in 2025, then soared by 61.4% to $14928.0 in 2026.
The last three Capital Expenditures figures came in at $14928.0 (Q1 2026), $9249.0 (Q4 2025), and $3363.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	86.87 Bn	78.87 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	65.40 Bn	60.22 Bn	1.37 Bn	-
4	Moderna	59.36 Bn	54.22 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.91 Bn	28.60 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.17 Bn	9.78 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	251.02 Mn
10	Azitra	2.61 Mn	2.61 Mn	-	40,053.00

Download Data